Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?

BACKGROUND: Radium-223 dichloride (Ra-223 Xofigo) has recently been approved as an addition to the host of available therapies in the USA as a treatment option for metastatic castrate-resistant prostate cancer (mCRPC) with bone metastases. This study describes our initial experience in patients trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Gayed, Isis, Salama, Vivian, Dawood, Lydia, Canfield, Steven, Wan, David, Cai, Chunyan, Joseph, Usha, Amato, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135075/
https://www.ncbi.nlm.nih.gov/pubmed/30233247
http://dx.doi.org/10.2147/CMAR.S166218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135075/
https://www.ncbi.nlm.nih.gov/pubmed/30233247
http://dx.doi.org/10.2147/CMAR.S166218

Ejemplares similares